Firefly Neuroscience Enters into Collaboration with Bright Minds to Analyse Data Using AI Technology
Thursday, October 17, 2024
Firefly Neuroscience has announced a collaboration with Bright Minds Biosciences Inc.
BMB-101, a selective 5-HT2C receptor agonist, has shown strong activity in both in vitro and in vivo studies. It is believed to offer a better tolerance profile compared to similar compounds, thanks to its Gq-protein biased signalling and minimal beta-arrestin recruitment.
Bright Minds has partnered with Firefly to analyse data from the first-in-human Phase 1 study of its lead compound, BMB-101.
The study, which used Quantitative Electroencephalogram (qEEG) data, showed positive results. EEG recordings were conducted using a 19-electrode headset from Zeto™, a partner of Firefly.
Data was collected at various intervals, with recordings taken both before and after dosing on day 1 and day 7.
The data was then processed using Firefly’s advanced EEG analysis platform.
The compound is considered promising for several indications, including addiction treatment, where it may help reduce opioid intake and impulsive behaviours linked to drug use.
In addition, BMB-101 has demonstrated anticonvulsant effects in animal models, reducing the frequency and severity of seizures, making it a potential treatment for conditions such as Dravet Syndrome.
Following the successful completion of the Phase 1 trial, BMB-101 is now ready for Phase 2 development. Bright Minds intends to submit an Investigational New Drug application to move forward with further clinical trials.
Source: globenewswire.com
